TY - JOUR
T1 - ASBMT Practice Guidelines Committee Survey on Long-Term Follow-Up Clinics for Hematopoietic Cell Transplant Survivors
AU - Hashmi, Shahrukh K.
AU - Lee, Stephanie J.
AU - Savani, Bipin N.
AU - Burns, Linda
AU - Wingard, John R.
AU - Perales, Miguel Angel
AU - Palmer, Jeanne
AU - Chow, Eric
AU - Meyer, Everett
AU - Marks, David
AU - Mohty, Mohamad
AU - Inamoto, Yoshihiro
AU - Rodriguez, Cesar
AU - Nagler, Arnon
AU - Sauter, Craig
AU - Komanduri, Krishna V.
AU - Pidala, Joseph
AU - Hamadani, Mehdi
AU - Johnston, Laura
AU - Shah, Nina
AU - Shaughnessy, Paul
AU - Hamilton, Betty K.
AU - Majhail, Navneet
AU - Kharfan-Dabaja, Mohamed A.
AU - Schriber, Jeff
AU - DeFilipp, Zachariah
AU - Tarlock, Katherine G.
AU - Fanning, Suzanne
AU - Curtin, Peter
AU - Rizzo, J. Douglas
AU - Carpenter, Paul A.
N1 - Publisher Copyright:
© 2018 The American Society for Blood and Marrow Transplantation
PY - 2018/6
Y1 - 2018/6
N2 - Significant advances in hematopoietic cell transplantation (HCT) have increased the long-term survivorship of its recipients, but because of unique complications arising from radiation and chemotherapy, recipients require lifelong follow-up. To evaluate current survivorship or long-term follow-up (LTFU) clinics specifically for HCT survivors and to evaluate the potential barriers in their establishment, the American Society for Blood and Marrow Transplantation (ASBMT) Practice Guidelines Committee electronically surveyed 200 HCT programs to gather quantitative and qualitative data about models of care. Among 77 programs (38.5%) that responded, 45% indicated presence of an LTFU clinic; however, LTFU care models varied with respect to services provided, specialist availability, type of patients served, and staffing. Among 55% of programs without an LTFU clinic, 100% agreed that allogeneic HCT survivors have unique needs separate from graft-versus-host disease and that complications could arise during the transition of care either from pediatric to adult settings or away from the HCT center. Lack of expertise, logistics, financial issues, and the observation that 84% of individual practitioners prefer to provide survivorship care were the identified obstacles to establishing new LTFU clinics. The ASBMT hopes that policymakers, HCT providers, and institutions will benefit from the results of this survey and recommends that delivering guidelines-driven screening and expert management of late effects is the goal of first-rate HCT survivorship care.
AB - Significant advances in hematopoietic cell transplantation (HCT) have increased the long-term survivorship of its recipients, but because of unique complications arising from radiation and chemotherapy, recipients require lifelong follow-up. To evaluate current survivorship or long-term follow-up (LTFU) clinics specifically for HCT survivors and to evaluate the potential barriers in their establishment, the American Society for Blood and Marrow Transplantation (ASBMT) Practice Guidelines Committee electronically surveyed 200 HCT programs to gather quantitative and qualitative data about models of care. Among 77 programs (38.5%) that responded, 45% indicated presence of an LTFU clinic; however, LTFU care models varied with respect to services provided, specialist availability, type of patients served, and staffing. Among 55% of programs without an LTFU clinic, 100% agreed that allogeneic HCT survivors have unique needs separate from graft-versus-host disease and that complications could arise during the transition of care either from pediatric to adult settings or away from the HCT center. Lack of expertise, logistics, financial issues, and the observation that 84% of individual practitioners prefer to provide survivorship care were the identified obstacles to establishing new LTFU clinics. The ASBMT hopes that policymakers, HCT providers, and institutions will benefit from the results of this survey and recommends that delivering guidelines-driven screening and expert management of late effects is the goal of first-rate HCT survivorship care.
UR - http://www.scopus.com/inward/record.url?scp=85046667868&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046667868&partnerID=8YFLogxK
U2 - 10.1016/j.bbmt.2018.03.023
DO - 10.1016/j.bbmt.2018.03.023
M3 - Article
C2 - 29608957
AN - SCOPUS:85046667868
SN - 1083-8791
VL - 24
SP - 1119
EP - 1124
JO - Biology of Blood and Marrow Transplantation
JF - Biology of Blood and Marrow Transplantation
IS - 6
ER -